株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

インターロイキン2 (T細胞増殖因子またはアルデスロイキンまたはIL2) :パイプライン製品の分析

Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 364830
出版日 ページ情報 英文 64 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.38円で換算しております。
Back to Top
インターロイキン2 (T細胞増殖因子またはアルデスロイキンまたはIL2) :パイプライン製品の分析 Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Pipeline Review, H2 2016
出版日: 2016年11月09日 ページ情報: 英文 64 Pages
概要

当レポートでは、インターロイキン2 (T細胞増殖因子またはアルデスロイキンまたはIL2) を標的とした治療薬の開発に関する情報を提供しており、開発段階、薬剤標的、作用機序、投与経路および分子タイプ別の分析、治療薬の開発に従事している企業の概要、最新ニュースやプレスリリースなどの情報をお届けします。

イントロダクション

  • 調査範囲

インターロイキン2 (T細胞増殖因子またはアルデスロイキンまたはIL2) の概要

治療薬の開発

インターロイキン2 (T細胞増殖因子またはアルデスロイキンまたはIL2):開発中の製品 - 開発段階別

インターロイキン2 (T細胞増殖因子またはアルデスロイキンまたはIL2):開発中の製品 - 治療範囲別

インターロイキン2 (T細胞増殖因子またはアルデスロイキンまたはIL2):開発中の製品 - 適応症別

インターロイキン2 (T細胞増殖因子またはアルデスロイキンまたはIL2):パイプライン製品の概況

  • 後期段階の製品
  • 初期段階の製品

インターロイキン2 (T細胞増殖因子またはアルデスロイキンまたはIL2):企業で開発中の製品

インターロイキン2 (T細胞増殖因子またはアルデスロイキンまたはIL2):大学/機関で開発中の製品

インターロイキン2 (T細胞増殖因子またはアルデスロイキンまたはIL2):治療薬の評価

  • 単剤療法/併用療法製品別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

インターロイキン2 (T細胞増殖因子またはアルデスロイキンまたはIL2) の治療薬開発に従事している企業

  • Alkermes Plc
  • Biomar Microbial Technologies
  • Cyxone AB
  • OncBioMune Pharmaceuticals Inc.
  • Transgene SA
  • ZIOPHARM Oncology, Inc.

薬剤プロファイル

インターロイキン2 (T細胞増殖因子またはアルデスロイキンまたはIL2):休止中のプロジェクト

インターロイキン2 (T細胞増殖因子またはアルデスロイキンまたはIL2):開発が中止された製品

インターロイキン2 (T細胞増殖因子またはアルデスロイキンまたはIL2):主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC0647TDB

Summary

Global Markets Direct's, 'Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Pipeline Review, H2 2016', provides in depth analysis on Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2)
  • The report reviews Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) Overview
  • Therapeutics Development
    • Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Products under Development by Stage of Development
    • Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Products under Development by Therapy Area
    • Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Products under Development by Indication
  • Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Products under Development by Companies
  • Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Products under Development by Universities/Institutes
  • Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Companies Involved in Therapeutics Development
    • Alkermes Plc
    • Biomar Microbial Technologies
    • Cyxone AB
    • OncBioMune Pharmaceuticals Inc.
    • Transgene SA
    • ZIOPHARM Oncology, Inc.
  • Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Drug Profiles
    • ALKS-4230 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Anti-PD1 Antibody + TILT-123 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologic to Activate IL-2 for Graft Versus Host Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BNZ-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Chimeric Antigen Receptor T Cell + TILT-123 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IB-08C175 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Prostatac - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • T-20K - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TG-4010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TILT-123 + Tumor Infiltrating Lymphocytes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target CD80 and IL-2 for Acute Myeloblastic Leukemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target IL-2 and E7 Protein for Cervical Cancer and Oropharyngeal Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Dormant Projects
  • Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Discontinued Products
    • Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Featured News & Press Releases
      • Oct 24, 2016: Immunotherapy Expert Dr. Brian Barnett Joins OncBioMune Scientific Advisory Board
      • Oct 19, 2016: OncBioMune Receives Notice of Patent Allowance for Novel Cancer Vaccine ProscaVax in Mexico
      • Sep 26, 2016: OncBioMune CEO Dr. Jonathan Head to Present Abstract on Prostate Cancer Vaccine at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science Into Survival
      • Aug 08, 2016: Latest Data From Phase 1 Trial of ProscaVax for Prostate Cancer Reinforces Safety and Benefit of Novel Cancer Vaccine
      • Jul 20, 2016: Pre-Clinical Research Supports Additional Studies of OncBioMune Technology for Breast Cancer Vaccine
      • Jul 13, 2016: OncBioMune Submits Protocol to Initiate Phase 2/3 Trial of ProscaVax for Prostate Cancer
      • Jun 14, 2016: OncBioMune Provides Corporate Update; ASCO Reinforces Market Opportunity for New Prostate Cancer Vaccine as Phase 2 Trial Approaches
      • Jun 02, 2016: Mexican Regulatory Authorities Supportive of OncBioMunes Phase 2 of ProscaVax for Prostate Cancer
      • May 25, 2016: Alkermes Announces Initiation of Phase 1 Clinical Study of Immuno-Oncology Drug Candidate ALKS 4230
      • May 18, 2016: Doctors Voice Optimism About Phase 2 Trial of ProscaVax in Mexico for Prostate Cancer
      • May 11, 2016: OncBioMune Provides Update on Phase 2 Clinical Trials of ProscaVax for Prostate Cancer
      • May 04, 2016: OncBioMune Submits Protocol to Principal Investigators for Two Phase 2 Clinical Trials of ProscaVax for Prostate Cancer
      • Apr 28, 2016: OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax in China
      • Apr 12, 2016: OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax in Hong Kong
      • Mar 29, 2016: Multiple sclerosis: plant peptide could prevent onset of the disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Alkermes Plc, H2 2016
  • Pipeline by Biomar Microbial Technologies, H2 2016
  • Pipeline by Cyxone AB, H2 2016
  • Pipeline by OncBioMune Pharmaceuticals Inc., H2 2016
  • Pipeline by Transgene SA, H2 2016
  • Pipeline by ZIOPHARM Oncology, Inc., H2 2016
  • Dormant Projects, H2 2016
  • Dormant Projects (Contd..1), H2 2016
  • Dormant Projects (Contd..2), H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top